Incidence and Risk Factors for Incomplete HBV DNA Suppression in HIV/HBV-Coinfected Patients Initiating Tenofovir-Based Therapy

Suppression of hepatitis B virus (HBV) DNA to undetectable levels is an important goal for HIV/HBV-coinfected patients receiving anti-HBV-active antiretroviral therapy (ART), and current guidelines recommend that this outcome should be reached by one year of treatment. However, the proportion of pat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hafkin, Jeffrey S., Osborn, Melissa K., Localio, A. Russell, Amorosa, Valerianna K., Kostman, Jay R., Stern, John J., De La Torre, Pola, Mounzer, Karam, Frank, Ian, Gross, Robert, Chang, Kyong-Mi, Lo Re, Vincent
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950944/
https://ncbi.nlm.nih.gov/pubmed/24597697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.12142
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi